Market Highlights

TB is the second disease with the highest mortality rate in the globe, after HIV/AIDS. It is caused by bacteria called Mycobacterium tuberculosis that infect the lungs; however, the bacteria can remain dormant for years without showing any symptoms. Increasing prevalence of diseases and increasing awareness regarding immunization and vaccination will drive the growth of the market over the forecast period. The government agencies and Non-Government Organizations (NGOs) are making joint efforts to control the spreads of the disease, which, in turn, contribute to the growth of the market. To get approval from the government for vaccine production and the side effects may hinder the growth of the market.

The tuberculosis vaccine treatment market is projected to reach USD 80.08 Million by 2030 at 5.67% CAGR during the forecast period 2022-2030.

Tuberculosis (TB) is a global health concern, with millions of people affected each year. Despite significant progress in TB prevention and treatment, it remains a major public health challenge. Vaccination has been a cornerstone in the fight against TB, and recent developments in the TB vaccine treatment market offer promising solutions. In this article, we will explore the current state of the TB vaccine treatment market, including key advancements and future opportunities.

Since it significantly increases morbidity and mortality globally, tuberculosis (TB) has been a long-standing global health concern. Although there has been a significant decline in TB incidence in recent years, there is still a critical need for more efficient prevention and treatment methods. There is hope in the fight against this fatal infectious illness because to the substantial progress being made in the development of tuberculosis vaccines and therapies. In this article, we examine the existing situation and potential growth in the market for tuberculosis vaccine treatments.

Segmentation:

The global tuberculosis vaccine treatment market is segmented on the basis of type of the test, type of TB vaccines, and end users. On the basis of type of the test, it is segmented into tuberculin skin test (TST), TB blood tests, IGRAs (interferon-gamma release assays), and others. On the basis, of type of Tb vaccines, it is segmented into immunotherapeutic vaccines, booster vaccines, and others. And on the basis of end users, it is segmented into hospitals, private clinics, research institutions, and others.

Regional Analysis

On the regional basis, the global tuberculosis vaccine treatment market is segmented into America, Europe, Asia Pacific and the Middle East & Africa. America accounts for the largest market in the world. The government have taken initiatives for vaccination against diseases like TB, as well as excellent management of public awareness programs are boosting the growth of this market in America. Europe is the second largest market owing to availability of funds for research and development activities and growing emphasis on R&D. The government in developing countries in Asia Pacific has undertaken various vaccinations programs. National Health Mission in India provides vaccination against various diseases such as TB, diphtheria, pertussis, tetanus, and polio. Asia Pacific shows the fastest growth in this market due to an increase in prevalence of communicable diseases. India is expected to be an emerging and the fastest growing market. The market shows steady growth in the Middle East & Africa due the demand for TB vaccine is less than other regions across the globe.
Some of the key players in the global tuberculosis vaccine treatment market are Merck & Co., Inc.(US), Sanofi Pasteur SA (France), Serum Institute of India Pvt. Ltd. (India), GlaxoSmithKline plc (UK), IDT Biologics GmbH, GreenSignal Bio Pharma Limited (India), Taj Pharmaceuticals Limited (India), Bavarian Nordic(US), Solvay(US), Informa plc.(US)

GlaxoSmithKline plc. Is a British pharmaceutical company, headquartered in Brentford, London. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham. It has the second highest listing on New York Stock Exchange. Legacy products developed by GSK are listed in the World Health Organization Model Lists of Essential Medicines.

Sanofi Pasteur, headquartered in France, is one of the leading players in the world producing human vaccines. Combination vaccines that protect against multiple diseases are one of the strengths of Sanofi Pasteur's products. The largest portfolio of vaccines for travelers and people living in tropical areas are tuberculosis, typhoid, rabies, yellow fever, Japanese encephalitis, meningococcal meningitis, cholera, hepatitis A, hepatitis B.

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), & Consulting Services. MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients.

Contact us:

Market Research Future (part of Wantstats Research and Media Private Limited),

99 Hudson Street, 5Th Floor,

New York, New York 10013

United States of America

+1 628 258 0071

Email: sales@marketresearchfuture.com